NewGenIvf Group Ltd NIVF
Misc Health and Biotechnology Services · data as of November 13, 2026
NewGenIvf Group Ltd (NIVF) is a healthcare company listed in the US with a market value of about $2M.
Its overall Stock Analiz score is 1.0 out of 5 (weak). The strongest part is value (2/5); the weakest is future growth (0/5).
Key numbers: a P/E of 0.2, a 5-year average ROIC of 1%.
About NewGenIvf Group
NewGenIvf Group is listed in the US and classified in misc health and biotechnology services. Revenue went from $4M in 2021 to $5M in 2024, growth of about 9.7% a year. It was profitable in 3 of the last 5 years in our data.
Score: 1.0 / 5
Checks passed
- P/E below 25
- P/E below the industry median
- ROE above 15%
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
- 3-year free cash flow growth above 10% a year
- Strong R&D investment or growth above 20%
Valuation
Growth and quality
Financials, last 5 years
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | — | $5M | $5M | $6M | $4M |
| Net income | $10M | -$524643 | $130193 | $458667 | -$533 |
| Free cash flow | -$11M | -$8M | -$2M | $2M | $1M |
| EPS (diluted) | $1.00 | $-0.05 | $0.01 | $0.05 | $-0.00 |
| Net margin | — | -9.7% | 2.5% | 7.7% | -0.0% |
| ROIC | -30.9% | — | 0.8% | 31.8% | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
What is NewGenIvf Group’s P/E ratio?
About 0.2, based on the last twelve months of diluted earnings per share.
Does NewGenIvf Group pay a dividend?
Not currently.
Is NewGenIvf Group a good stock to buy?
We do not give buy or sell advice. NewGenIvf Group scores 1.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.